HumanFX is proud to have been approved by the Institutional Review Board (IRB) of the Institute of Cellular Regenerative Medicine for a clinical trial on the Safety and Efficacy of Human Living Cells (StemPlate™) for the Treatment of Osteoarthritis, Protocol #HRI-SP-OA-01.
HumanFX is offering the StemPlate™ treatment to its patients as part of this clinical trial. If interested in participating in the clinical trial, please click on the link below.
Questions? Call us toll free at 1-888-664-0040.
The Institute of Cellular Regenerative Medicine supports the practice of regenerative medicine while upholding standards set by the Department of Health and Human Resources and the Helsinki protocol for ethical treatment of patients, safety concerns and practical scientific oversight. The IRB, also known as an independent ethics committee or ethical review board, is the committee that is designated to approve, oversee, monitor and review the StemPlate™ clinical trial. The IRB’s purpose is to assure, throughout the clinical trial, that appropriate steps are taken to protect the rights and welfare of the participants in the clinical trial. A key goal of the IRBs is to protect human subjects from physical or psychological harm, by assessing the ethics of the research and its methods, promoting fully informed and voluntary participation by prospective participants capable of making such choices (or, if that is not possible, informed permission given by a suitable proxy), and seeking to maximize the safety of all participants.